Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Henry Schein Stock: Analyst Estimates & Ratings
Henry Schein Stock: Analyst Estimates & Ratings
Henry Schein Inc_ logo on phone-by Piotr Swat via Shuttestock
Anushka Mukherjee
Tue, February 17, 2026 at 12:39 AM GMT+9 2 min read
In this article:
HSIC
-0.31%
^GSPC
+0.05%
Founded in 1932, Melville, New York-based Henry Schein, Inc. (HSIC) provides health care products and services to office-based dental and medical practitioners, and alternate sites of care worldwide. The company has a market capitalization of $9.2 billion and operates through Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology segments.
The company’s shares have underperformed the broader market over the past year but have slightly outperformed in 2026. HSIC stock has grown marginally over the past 52 weeks and 3.5% on a YTD basis. In comparison, the S&P 500 Index ($SPX) has returned 11.8% over the past year and declined marginally in 2026.
More News from Barchart
Narrowing the focus, HSIC has also underperformed the State Street Healthcare Select Sector SPDR ETF’s (XLV) 7.7% rise over the past 52 weeks.
www.barchart.com
HSIC has turned into somewhat of a worrisome stock for investors in recent years. The company has experienced no organic revenue growth over the past two years, suggesting that future acquisitions, which would require significant capital expenditures, may be needed to drive growth. Additionally, HSIC has seen a 2.8% decline in its free cash flow margin over the last five years, reflecting increased investment to defend its market position.
More recently, the stock closed down more than 2% after appointing Fedd Lowery as the next CEO to replace Stanley Begman, who earlier said he would retire effective March 2. This news did the bade well with investors, leading to a fall in its price in the trading session.
For the current year, which ended in December 2025, analysts expect HSIC’s EPS to grow 3.6% YoY to $4.91 on a diluted basis. The company’s earnings surprise history is mixed. It surpassed or matched the consensus estimate in three of the last four quarters and missed on one occasion.
Among the 16 analysts covering HSIC stock, the consensus is a “Moderate Buy.” That’s based on six “Strong Buy” ratings, nine “Holds,” and one “Strong Sell.
www.barchart.com
On Jan. 20, Mizuho Securities analyst Steven Valiquette maintained a “Hold” rating on Henry Schein stock and set a price target of $81. HSIC’s mean price target of $78.14 sits below its current market prices. Its Street-high target of $90 suggests the stock could rally by up to 15.1%.
_ On the date of publication, Anushka Mukherjee did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com _
Condiciones y Política de privacidad
Privacy Dashboard
More Info